|
1
|
Elkins DB, Haswell-Elkins MR, Mairiang E,
Mairiang P, Sithithaworn P, Kaewkes S, Bhudhisawasdi V and
Uttaravichien T: A high frequency of hepatobiliary disease and
suspected cholangiocarcinoma associated with heavy Opisthorchis
viverrini infection in a small community in north-east Thailand.
Trans R Soc Trop Med Hyg. 84:715–719. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Elkins DB, Mairiang E, Sithithaworn P,
Mairiang P, Chaiyakum J, Chamadol N, Loapaiboon V and
Haswell-Elkins MR: Cross-sectional patterns of hepatobiliary
abnormalities and possible precursor conditions of
cholangiocarcinoma associated with Opisthorchis viverrini infection
in humans. Am J Trop Med Hyg. 55:295–301. 1996.PubMed/NCBI
|
|
3
|
Sripa B and Pairojkul C:
Cholangiocarcinoma: Lessons from Thailand. Curr Opin Gastroenterol.
24:349–356. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Khan SA, Thomas HC, Davidson BR and
Taylor-Robinson SD: Cholangiocarcinoma. Lancet. 366:1303–1314.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shaib Y and El-Serag HB: The epidemiology
of cholangiocarcinoma. Semin Liver Dis. 24:115–125. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Khan SA, Taylor-Robinson SD, Toledano MB,
Beck A, Elliott P and Thomas HC: Changing international trends in
mortality rates for liver, biliary and pancreatic tumours. J
Hepatol. 37:806–813. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Khuntikeo N, Pugkhem A, Titapun A and
Bhudhisawasdi V: Surgical management of perihilar
cholangiocarcinoma: A Khon Kaen experience. J Hepatobiliary
Pancreat Sci. 21:521–524. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ihle JN: The Stat family in cytokine
signaling. Curr Opin Cell Biol. 13:211–217. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Takeda K and Akira S: STAT family of
transcription factors in cytokine-mediated biological responses.
Cytokine Growth Factor Rev. 11:199–207. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bromberg J: Stat proteins and oncogenesis.
J Clin Invest. 109:1139–1142. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Smirnova OV, Ostroukhova TY and Bogorad
RL: JAK-STAT pathway in carcinogenesis: Is it relevant to
cholangiocarcinoma progression? World J Gastroenterol.
13:6478–6491. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yu H, Pardoll D and Jove R: STATs in
cancer inflammation and immunity: A leading role for STAT3. Nat Rev
Cancer. 9:798–809. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dokduang H, Juntana S, Techasen A, Namwat
N, Yongvanit P, Khuntikeo N, Riggins GJ and Loilome W: Survey of
activated kinase proteins reveals potential targets for
cholangiocarcinoma treatment. Tumour Biol. 34:3519–3528. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Loilome W, Juntana S, Namwat N,
Bhudhisawasdi V, Puapairoj A, Sripa B, Miwa M, Saya H, Riggins GJ
and Yongvanit P: PRKAR1A is overexpressed and represents a possible
therapeutic target in human cholangiocarcinoma. Int J Cancer.
129:34–44. 2011. View Article : Google Scholar
|
|
15
|
Dokduang H, Techasen A, Namwat N,
Khuntikeo N, Pairojkul C, Murakami Y, Loilome W and Yongvanit P:
STATs profiling reveals predominantly-activated STAT3 in
cholangiocarcinoma genesis and progression. J Hepatobiliary
Pancreat Sci. 21:767–776. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
González-Vallinas M, González-Castejón M,
Rodríguez-Casado A and Ramírez de Molina A: Dietary phytochemicals
in cancer prevention and therapy: A complementary approach with
promising perspectives. Nutr Rev. 71:585–599. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Landis-Piwowar KR and Iyer NR: Cancer
chemoprevention: Current state of the art. Cancer Growth
Metastasis. 7:19–25. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Murakami A, Ohigashi H and Koshimizu K:
Anti-tumor promotion with food phytochemicals: A strategy for
cancer chemoprevention. Biosci Biotechnol Biochem. 60:1–8. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Surh YJ: Cancer chemoprevention with
dietary phytochemicals. Nat Rev Cancer. 3:768–780. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gerhauser C, Alt A, Heiss E, Gamal-Eldeen
A, Klimo K, Knauft J, Neumann I, Scherf HR, Frank N, Bartsch H, et
al: Cancer chemopreventive activity of Xanthohumol, a natural
product derived from hop. Mol Cancer Ther. 1:959–969.
2002.PubMed/NCBI
|
|
21
|
Albini A, Dell Eva R, Vené R, Ferrari N,
Buhler DR, Noonan DM and Fassina G: Mechanisms of the
antiangiogenic activity by the hop flavonoid xanthohumol: NF-kappaB
and Akt as targets. FASEB J. 20:527–529. 2006.PubMed/NCBI
|
|
22
|
Dell'Eva R, Ambrosini C, Vannini N,
Piaggio G, Albini A and Ferrari N: AKT/NF-kappaB inhibitor
xanthohumol targets cell growth and angiogenesis in hematologic
malignancies. Cancer. 110:2007–2011. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Harikumar KB, Kunnumakkara AB, Ahn KS,
Anand P, Krishnan S, Guha S and Aggarwal BB: Modification of the
cysteine residues in IkappaBalpha kinase and NF-kappaB (p65) by
xanthohumol leads to suppression of NF-kappaB-regulated gene
products and potentiation of apoptosis in leukemia cells. Blood.
113:2003–2013. 2009. View Article : Google Scholar
|
|
24
|
Monteghirfo S, Tosetti F, Ambrosini C,
Stigliani S, Pozzi S, Frassoni F, Fassina G, Soverini S, Albini A
and Ferrari N: Antileukemia effects of xanthohumol in
Bcr/Abl-transformed cells involve nuclear factor-kappaB and p53
modulation. Mol Cancer Ther. 7:2692–2702. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Namwat N, Amimanan P, Loilome W,
Jearanaikoon P, Sripa B, Bhudhisawasdi V and Tassaneeyakul W:
Characterization of 5-fluorouracil-resistant cholangiocarcinoma
cell lines. Chemotherapy. 54:343–351. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Blando JM, Carbajal S, Abel E, Beltran L,
Conti C, Fischer S and DiGiovanni J: Cooperation between Stat3 and
Akt signaling leads to prostate tumor development in transgenic
mice. Neoplasia. 13:254–265. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kortylewski M, Feld F, Krüger KD,
Bahrenberg G, Roth RA, Joost HG, Heinrich PC, Behrmann I and
Barthel A: Akt modulates STAT3-mediated gene expression through a
FKHR (FOXO1a)-dependent mechanism. J Biol Chem. 278:5242–5249.
2003. View Article : Google Scholar
|
|
28
|
Squarize CH, Castilho RM, Sriuranpong V,
Pinto DS Jr and Gutkind JS: Molecular cross-talk between the
NFkappaB and STAT3 signaling pathways in head and neck squamous
cell carcinoma. Neoplasia. 8:733–746. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhou J, Wulfkuhle J, Zhang H, Gu P, Yang
Y, Deng J, Margolick JB, Liotta LA, Petricoin E III and Zhang Y:
Activation of the PTEN/mTOR/STAT3 pathway in breast cancer
stem-like cells is required for viability and maintenance. Proc
Natl Acad Sci USA. 104:16158–16163. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sano S, Itami S, Takeda K, Tarutani M,
Yamaguchi Y, Miura H, Yoshikawa K, Akira S and Takeda J:
Keratinocyte-specific ablation of Stat3 exhibits impaired skin
remodeling, but does not affect skin morphogenesis. EMBO J.
18:4657–4668. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Takeda K, Clausen BE, Kaisho T, Tsujimura
T, Terada N, Förster I and Akira S: Enhanced Th1 activity and
development of chronic enterocolitis in mice devoid of Stat3 in
macrophages and neutrophils. Immunity. 10:39–49. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Takeda K, Noguchi K, Shi W, Tanaka T,
Matsumoto M, Yoshida N, Kishimoto T and Akira S: Targeted
disruption of the mouse Stat3 gene leads to early embryonic
lethality. Proc Natl Acad Sci USA. 94:3801–3804. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bromberg JF, Horvath CM, Besser D, Lathem
WW and Darnell JE Jr: Stat3 activation is required for cellular
transformation by v-src. Mol Cell Biol. 18:2553–2558. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cao X, Tay A, Guy GR and Tan YH:
Activation and association of Stat3 with Src in v-Src-transformed
cell lines. Mol Cell Biol. 16:1595–1603. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Turkson J, Bowman T, Garcia R, Caldenhoven
E, De Groot RP and Jove R: Stat3 activation by Src induces specific
gene regulation and is required for cell transformation. Mol Cell
Biol. 18:2545–2552. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Isomoto H, Mott JL, Kobayashi S, Werneburg
NW, Bronk SF, Haan S and Gores GJ: Sustained IL-6/STAT-3 signaling
in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing.
Gastroenterology. 132:384–396. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sia D, Hoshida Y, Villanueva A, Roayaie S,
Ferrer J, Tabak B, Peix J, Sole M, Tovar V, Alsinet C, et al:
Integrative molecular analysis of intrahepatic cholangiocarcinoma
reveals 2 classes that have different outcomes. Gastroenterology.
144:829–840. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sia D, Tovar V, Moeini A and Llovet JM:
Intrahepatic cholangio-carcinoma: Pathogenesis and rationale for
molecular therapies. Oncogene. 32:4861–4870. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Techasen A, Loilome W, Namwat N, Dokduang
H, Jongthawin J and Yongvanit P: Cytokines released from activated
human macrophages induce epithelial mesenchymal transition markers
of cholangiocarcinoma cells. Asian Pac J Cancer Prev. 13(Suppl):
S115–S118. 2012.
|
|
40
|
Gerhäuser C: Beer constituents as
potential cancer chemopreventive agents. Eur J Cancer.
41:1941–1954. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Colgate EC, Miranda CL, Stevens JF, Bray
TM and Ho E: Xanthohumol, a prenylflavonoid derived from hops
induces apoptosis and inhibits NF-kappaB activation in prostate
epithelial cells. Cancer Lett. 246:201–209. 2007. View Article : Google Scholar
|
|
42
|
Monteiro R, Calhau C, Silva AO,
Pinheiro-Silva S, Guerreiro S, Gärtner F, Azevedo I and Soares R:
Xanthohumol inhibits inflammatory factor production and
angiogenesis in breast cancer xenografts. J Cell Biochem.
104:1699–1707. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Jongthawin J, Techasen A, Loilome W,
Yongvanit P and Namwat N: Anti-inflammatory agents suppress the
prostaglandin E2 production and migration ability of
cholangiocarcinoma cell lines. Asian Pac J Cancer Prev. 13(Suppl):
47–51. 2012.PubMed/NCBI
|
|
44
|
Liu B, Ren Z, Shi Y, Guan C, Pan Z and
Zong Z: Activation of signal transducers and activators of
transcription 3 and over-expression of its target gene CyclinD1 in
laryngeal carcinomas. Laryngoscope. 118:1976–1980. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Williams JG: STAT signalling in cell
proliferation and in development. Curr Opin Genet Dev. 10:503–507.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Logue JS and Morrison DK: Complexity in
the signaling network: Insights from the use of targeted inhibitors
in cancer therapy. Genes Dev. 26:641–650. 2012. View Article : Google Scholar : PubMed/NCBI
|
